Rubicon Research Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: RUBICON BSE: 544578
₹1619.40
▲ 10.40 (0.65%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
96/100
Strong
Valuation
—/100
Expensive
Momentum
30/100
Bearish

QVM read Quality, pricey and fading Quality Strong, Valuation Expensive, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Rubicon Research is an Indian pharmaceutical company located in Mumbai.

Source: Wikipedia

Key Metrics

Market Capitalization
₹26,782 Cr
PE (TTM)
111.8
Industry median 36.1 (152 companies)
Price to Book
20.8
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
16.95%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
45.4
Relative return vs Sector, qtr %
18.4
Free Cash Flow
₹-24 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
Data unavailable.
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
Data unavailable.
Revenue Growth (YoY)
Data unavailable.
Current Ratio
2.01
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.20
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
12.24
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
19.28%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
27.28%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
23.64%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
Data unavailable.
Return on Capital Employed
Data unavailable (needs a filed half-yearly balance sheet).
Return on Equity
Data unavailable (needs a filed half-yearly balance sheet).

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 3 met
  • Yes Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.20)
  • Yes Net cash flow for the latest year is positive

Ownership

1 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Value and momentum

0 of 5 met
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.6%
Low 1577.7000 · High 1635.0000
1W return
-3.3%
Low 1575.1000 · High 1695.9000
1M return
-11.0%
Low 1575.1000 · High 1880.5000
52W return
Data unavailable.
Low 570.7500 · High 1899.0000
Lifetime High ₹1860.6000 (Sept. 8, 2026)
Lifetime Low ₹577.2500 (Oct. 24, 2025)

Full price history and technicals →

EMA & SMA

Bullish2
Bearish4
5D
1634.8
10D
1670.0
20D
1702.9
50D
1650.9
100D
1479.8
200D
1115.0

Delivery and volume

Day avg. delivery
38.4%
Week avg. delivery
59.6%
Month avg. delivery
55.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1610.70
Pivot
First resistance1643.70
Second resistance1668.00
Third resistance1701.00
First support1586.40
Second support1553.40
Third support1529.10
Day RSI39.4
Day MFI25.7
Day MACD-23.36
Day MACD signal2.56

Beta

1M0.36
3M-0.18
1Y0.38
3Y0.38

Price change analysis

↓ -11.0%
Over 1 Month
LowHigh
1575.101880.50
↑ 18.4%
Over 3 Months
LowHigh
1286.301899.00
↑ 107.1%
Over 6 Months
LowHigh
762.451899.00
—
Over 1 Year
LowHigh
570.751899.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (June 30, 2026)
₹428 Cr
Net profit (June 30, 2026)
₹82 Cr
Basic EPS (June 30, 2026)
₹4.9900

Ranks #26 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter59.76%
  • Mutual funds7.23%
  • FII/FPI7.52%
  • Other DII2.20%
  • Public23.29%

Largest holders

NameCategoryShares %Shares
General Atlantic Singapore Rr Pte LtdPromoter35.8300%59258360
Shivanand Shankar Mankekar HUFPublic13.5200%22357230
Surabhi Parag SanchetiPromoter7.9200%13095000
Sumant PilgaonkarPromoter7.9000%13065000
Pratibha Sudhir PilgaonkarPromoter3.8900%6435000

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings decreased from 59.86% to 59.76% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 7.54% to 7.52% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 7.14% to 7.23% in Jun 2026 qtr

6 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 0 insider trades, 2 SAST, 0 pledge events →

All insider and SAST disclosures →

DateClientDealActionQuantityPriceExchange
26 Aug 2026 GENERAL ATLANTIC SINGAPORE RR PTE LTD Bulk Sell 843,372 1660.0000 NSE
26 Aug 2026 ARANDA INVESTMENTS PTE. LTD. Bulk Buy 843,372 1660.0000 NSE
26 Aug 2026 GENERAL ATLANTIC SINGAPORE RR PTE LTD Block Sell 843,372 1660.0000 NSE
26 Aug 2026 ARANDA INVESTMENTS PTE. LTD. Block Buy 843,372 1660.0000 NSE
26 Aug 2026 VEMF-A , LP Block Buy 150,605 1660.0000 BSE
26 Aug 2026 GENERAL ATLANTIC SINGAPORE RR PTE LTD Block Sell 150,605 1660.0000 BSE
26 Aug 2026 PI OPPORTUNITIES AIF V LLP Block Buy 301,202 1660.0000 BSE
26 Aug 2026 TIMF HOLDINGS Block Buy 903,610 1660.0000 BSE
26 Aug 2026 AXIS MUTUAL FUND Block Buy 903,611 1660.0000 BSE
26 Aug 2026 NOMURA INDIA INVESTMENT FUND MOTHER FUND Block Buy 1,203,999 1660.0000 BSE

All bulk and block deals →

Last 12 months ₹1.50 per share
Dividend yield 0.09%
Ex-dateSubjectPer share (₹)Record date
7 Aug 2026 Dividend - Rs 1.50 Per Share 1.5000 7 Aug 2026

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
14 Aug 2026 Financial Results Yes
29 May 2026 Financial Results/Dividend Yes
3 Feb 2026 Financial Results Yes
13 Nov 2025 Financial Results Yes

Corporate Announcements

All 81 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.20)
  • Comfortable interest coverage (12.2x)
  • Healthy liquidity (Current Ratio 2.01)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

  • PE above 35 (111.8) -- priced for continued strong execution

Data unavailable (no single-stock futures or options activity on record for this company).

Part of: NIFTY 500

Frequently asked questions about Rubicon Research Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.